Shares of Cadila Healthcare were quoted at Rs 341.15 each at market close on Monday. The stock has been losing for the last 2 days and has fallen more than a percent during the period.
Recommended ArticlesView All
New Locker Rules — Here's why the RBI has gone overboard
Jan 28, 2023 IST5 Min(s) Read
Meet Padma Shri Awardee Guru K Kalyanasundaram Pillai, the man who is keeping an ancient tradition alive
Jan 27, 2023 IST3 Min(s) Read
This is how the new draft IT rules propose to make online gaming safe
Jan 27, 2023 IST4 Min(s) Read
78 percent Indian workers uneasy about job security amid layoffs: Survey
Jan 27, 2023 IST5 Min(s) Read
The stock is just 3 percent away from hitting its 52-week low of Rs 330.65. The 52-week highest was Rs. 456.75.
The stock has traded lower than 5 day, 20 day, 50 day, 100 day and 200 day moving average.
Year-to-date, Cadila Healthcare has underperformed by over 21 percent. Interestingly, the largecap pharma stock has returned more than 68 percent in the last five years and a whopping over 862 percent in the last 10 years.
On Monday, Zydus Cadila informed bourses that it has received final approval from the US health regulator to market Doxycycline Hyclate delayed-release tablets, used to treat bacterial infections.
The United States Food and Drug Administration (USFDA) approval pertains to allowing the company to market the drug in the strengths of 75 mg, 100 mg and 150 mg, Cadila Healthcare informed the BSE in an exchange filing.
Meanwhile, Nifty Pharma ended more than half a percent lower on Monday with as many as 7 stocks declining against just 3 advances.
Gainers included Glenmark, Piramal and Cipla, rising by up to 0.89 percent. Shares of Lupin, Biocon and Divi’s Labs were among the top laggards.
The 50-share broader Nifty50 shed over 90 points to settle below 10,700, closing at 10,663.
First Published: Dec 25, 2018 1:54 PM IST